ERBB2 and ductal breast carcinoma in situ: Some studies have linked high basal expression of SPARC with a poor prognosis and decreased survival in breast cancer patients with HER2+ 26, invasive ductal carcinoma 27, and a shorter time to recurrence in patients with ductal carcinoma in situ 28.